Log In
Print
BCIQ
Print
Print this Print this
 

Inavir, laninamivir octanoate (CS-8958)

Also known as: CS8958

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionSecond-generation long-acting neuraminidase inhibitor (LANI)
Molecular Target Neuraminidase
Mechanism of ActionNeuraminidase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent influenza A and B infection in people over 10 years of age; Prevent transmission of influenza A and B infection to other family members of a patient with confirmed influenza infection; Treat influenza A and B in adults and children; Treat influenza in geriatric patients; Treat influenza infection; Treat influenza type A or B virus infection in pediatric patients
Regulatory Designation

Japan - Standard Review (Prevent transmission of influenza A and B infection to other family members of a patient with confirmed influenza infection)

Partner

Biota Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today